Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines (Q39026347)

8 September 2017

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines (English)

1 reference

8 September 2017

Frauke Ringel

1

1 reference

8 September 2017

Jaspal Kaeda

2

1 reference

8 September 2017

Michaela Schwarz

3

1 reference

8 September 2017

Christian Oberender

4

1 reference

8 September 2017

Peggy Grille

5

1 reference

8 September 2017

Bernd Dörken

6

1 reference

8 September 2017

Fanny Marque

7

1 reference

8 September 2017

Paul W Manley

8

1 reference

8 September 2017

Thomas Radimerski

9

1 reference

8 September 2017

Philipp le Coutre

10

1 reference

8 September 2017

31 January 2014

1 reference

8 September 2017

1 reference

8 September 2017

132

1 reference

8 September 2017

1

1 reference

8 September 2017

75-86

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

8 September 2017

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase

21 January 2018

1 reference

Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction

21 January 2018

1 reference

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

21 January 2018

1 reference

JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

21 January 2018

1 reference

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

21 January 2018

1 reference

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

21 January 2018

1 reference

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)

21 January 2018

1 reference

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

21 January 2018

1 reference

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

21 January 2018

1 reference

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

21 January 2018

1 reference

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

21 January 2018

1 reference

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

21 January 2018

1 reference

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

21 January 2018

1 reference

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

21 January 2018

1 reference

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

21 January 2018

1 reference

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells

21 January 2018

1 reference

STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

21 January 2018

1 reference

BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor

21 January 2018

1 reference

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

21 January 2018

1 reference

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling

21 January 2018

1 reference

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

21 January 2018

1 reference

Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment

21 January 2018

1 reference

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations

21 January 2018

1 reference

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000356784

1 reference

8 September 2017

1 reference